Appeal No. 2004-0250 Page 2
Application No. 09/226,412
Claims 30, 50, and 59 are representative of the subject matter on appeal and read as
follows:
30. A method of administering a monomeric insulin analog comprising,
administering an effective amount of the monomeric insulin analog to a patient in need
thereof by pulmonary means, wherein said monomeric insulin analog:
a) is selected from the group consisting of modified human insulins wherein:
i) the amino acid residue at position B28 is substituted with Lys, Leu, Val,
Asp, or Ala, and the amino acid residue at position B29 is Lys or Pro;
ii) the amino acid residues at positions B28, B29, and B30 are deleted; or
iii) the amino acid residue at position B27 is deleted; and
b) is inhaled through the mouth of said patient.
50. A method for treating diabetes comprising, administering an effective dose
of monomeric insulin analog to a patient in need thereof by pulmonary means.
59. A method for treating hyperglycemia comprising, administering an
effective does of a monomeric insulin analog to a patient in need thereof by pulmonary
means.
The reference relied upon by the examiner is:
Jensen et al. (Jensen) 5,898,028 Apr. 27, 19992
2 Jensen was filed on March 20, 1998, and is stated to be related to Provisional
Application No. 60/041648 filed on March 27, 1997. In addition, the face of the Jensen
Patent indicates that a claim for priority under 35 U.S.C. § 119 is made on the basis of
Denmark 0319/97 filed on March 20, 1997.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007